Medical News

RSS

African leaders must invest in malaria prevention

In a Daily Caller opinion piece, Richard Tren, director of Africa Fighting Malaria, highlights a finding in a recent malaria report that the U.S. government and the Bill & Melinda Gates Foundation "were responsible for 85% of the steep increase in malaria funding between 2007 and 2009." But "[i]f 30 African heads of state were to give up their private jets, a fund of well over $500 million could be generated," Tren writes.

25 Jul 2011

Waters receives CE mark for MassTrak Immunosuppressants XE Kit

Waters Corporation (NYSE: WAT) today announced that its MassTrak™ Immunosuppressants XE Kit is now CE-marked in accordance with the IVD Directive 98/79/EC, for the quantitative measurement of the immunosuppressive drugs tacrolimus in liver and kidney transplant patients and everolimus in adult kidney and cardiac transplant patients from human whole blood samples as an aid in the management of immunosuppressant drug therapy.

25 Jul 2011

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.

25 Jul 2011

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold Pharmaceuticals, Inc., today announced that the University of Texas at San Antonio initiated a clinical trial of TH-302 in combination with bevacizumab in patients with recurrent high grade astrocytoma including glioblastoma.

25 Jul 2011

Bionovo completes 13 weeks repeat dose animal toxicology studies for Menerba

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today the successful completion of 13 weeks repeat dose animal toxicology studies with Menerba.

25 Jul 2011

Talks between automakers, UAW focus on health care costs

One big target for the three U.S. automakers in talks beginning this week with the United Auto Workers for new labor agreements will be the $1.54 billion collectively spent by the companies last year on health care for union members and their families.

25 Jul 2011

Sunshine Heart to sell 115 million shares of common stock in private placement

Sunshine Heart, Inc., today announced it has entered into definitive agreements with new and existing institutional investors in the United States and Canada to sell approximately 115 million shares of common stock in a private placement.

25 Jul 2011

Health providers embrace the potential of ACOs

News outlets report on some health care providers' views of the potential of accountable care organizations to improve quality and reduce costs.

25 Jul 2011

Ranbaxy announces launch of Letrozole Tablets in UK, Romania and France

Ranbaxy Laboratories Limited today announced the launch of Letrozole Tablets 2.5 mg in UK, Romania and France, on Day-1. Letrozole is the bio equivalent of Femara, the innovator product of Novartis, that has a market size of USD 58 Mn in UK, USD 95 Mn in France and USD 5.5 Mn in Romania.

25 Jul 2011

Australian TGA approves GI Dynamics EndoBarrier Gastrointestinal Liner for type 2 diabetes and obesity

GI Dynamics, Inc., a company focused on the development and commercialization of effective, non-surgical approaches for the treatment of type 2 diabetes and obesity, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the EndoBarrier® Gastrointestinal Liner for inclusion on the Australian Register of Therapeutic Goods (ARTG).

25 Jul 2011

Iowa, Kentucky get extra time to comply with MLR rule

But North Dakota became the first state to have the Department of Health and Human Services deny a waiver request regarding the health law's medical loss ratio provision, which requires health plans in the individual and small-group markets to spend no more than 20 percent of premiums on administrative costs.

25 Jul 2011

HCA second quarter revenues increase 4% to $8.063 billion

HCA Holdings, Inc. today announced financial and operating results for the second quarter ended June 30, 2011.

25 Jul 2011

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec announced today it has received conditional approval from the European Commission for FAMPYRA® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis who have walking disability.

25 Jul 2011

Some hospitals face hard times

Walter Reed Army Medical Center will close its doors after nearly a century. By month's end, the Shriners Hospitals will stop its tradition of providing free care to children. And, lastly, hospital bonds maybe vulnerable to downgrades because of potential reduction in Medicare reimbursements and Medicaid cuts.

25 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

Swaziland government, Vantage plan to construct pharmaceutical manufacturing facility

Vantage Health, announced today that it has been invited by the Ministry of Health for the Kingdom of Swaziland to plan the construction of a pharmaceutical manufacturing facility in that country.

25 Jul 2011

Roper Industries second quarter sales increase 23% to $700 million

Roper Industries, Inc. reported record financial results for the second quarter ended June 30, 2011.

25 Jul 2011

First Edition: July 25, 2011

Reporting for Kaiser Health News, Joanne Silberner writes about her recent conversation with George Halvorson, who offers his take on the future of health care under the 2010 Affordable Care Act, including the role ACOs are likely to play.

25 Jul 2011

MiMedx second quarter revenue increases 85% to $1,929,000

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the second quarter and six months ended June 30, 2011.

25 Jul 2011

Valeritas' V-Go Disposable Insulin Delivery Device receives CE Mark approval

Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced today it received CE Mark approval for its V-Go Disposable Insulin Delivery Device as well as ISO 13485: 2003 Quality Management System Certification.

25 Jul 2011